Sangui BioTech International Inc.: Sales of USD 88,001 in fiscal year 2019
Sangui BioTech:- Sales of USD 88,001 in fiscal year 2019
Witten, October, 09, 2019: In the fiscal year 2019 (01/07/2018 to 30/06/2019) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 88,001. In the same period of the previous year the comparable revenue amounted to USD 77,152. Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2019 increased by 14% compared to previous year. While revenues in the first half of the year were 15% higher than in the same period of the previous year, the increase in the second half of the year was slightly weaker at 13%.
As operating expenses increased USD 140,501 or 40% to USD 425,636 during the period, operating loss increased USD 129,590 to USD 337,635 from the prior year. The cause of this development was, among others, the restructuring costs associated with the closure of the Witten site on 30/06/2019.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact: Sangui Biotech International, Inc. Thomas Striepe Fax: +49 (40)46093120 e-mail: firstname.lastname@example.org
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
09.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de